FDA approves Nexviazyme for late-onset Pompe disease
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
All India Institute of Ayurveda hosts ministers and showcase their achievements
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
CDSCO to fast-track trials and approval for COVID19 vaccine
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
The company has been consistently reducing debt
Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.
It had an estimated market size of US $ 32 million as of June 2021
Subscribe To Our Newsletter & Stay Updated